Tempus AI and the University of Southern California have joined forces to transform cancer and precision care. Together, they aim to bring AI-driven diagnostics and personalized treatment tools directly into clinical settings. This collaboration marks a significant step forward for health systems investing in data-driven medicine.
Overview of the Partnership
Keck Medicine of USC and Tempus AI announced a strategic collaboration on April 23. The partnership integrates AI tools across USC’s broader health system. That system handles more than 1.5 million patient visits every year.
Two flagship institutions anchor this effort. They are the USC Norris Comprehensive Cancer Center and Keck Medicine of USC, both based in Los Angeles. Together, they bring clinical depth and research capacity to the table.
Tempus AI is a Chicago-based precision medicine company. It specializes in AI-powered genomic profiling and clinical data analysis. Furthermore, the company has built one of the largest libraries of clinical and molecular data in healthcare.
Why This Collaboration Matters
Precision medicine is changing how clinicians approach diagnosis and treatment. Instead of one-size-fits-all protocols, it tailors care to a patient’s genetic profile. This shift requires powerful data tools and AI integration — exactly what Tempus brings to the partnership.
Additionally, USC’s patient volume makes it an ideal environment to test and scale AI solutions. Larger datasets improve AI model performance. Consequently, more patients benefit from better-targeted interventions over time.
Health systems across the country are racing to adopt precision tools. However, translating pilots into clinical workflows remains a major challenge. This deal directly addresses that gap by embedding AI into existing care processes.
Four Key Focus Areas of the Deal
Clinical Testing
The partnership starts with clinical testing. Tempus’ genomic profiling tools will integrate directly into USC’s clinical workflows. Clinicians can then use molecular data to guide treatment decisions faster and with greater accuracy.
Clinical Trial Matching
Finding the right clinical trial for a patient is often slow and manual. Under this agreement, AI will streamline that process. The system will analyze patient profiles and match them to eligible trials in real time. As a result, more patients can access cutting-edge treatments sooner.
Identifying Care Gaps
AI will also help USC identify patients who are missing key interventions. These care gaps often go undetected in busy health systems. By surfacing them proactively, clinicians can act before conditions worsen. This approach supports both quality improvement and preventive care goals.
Joint Research and Development
Beyond clinical tools, both organizations will pursue joint R&D initiatives. They will collaborate on developing new diagnostics and therapeutic approaches. Moreover, this shared research agenda accelerates innovation beyond what either institution could achieve alone.
How Genomic Profiling Enters Clinical Workflows
Genomic data has long existed in silos. Traditionally, it stayed in labs and rarely reached bedside clinicians in a usable format. This partnership changes that dynamic entirely.
Tempus’ platform processes genomic results and presents them within existing clinical systems. Physicians receive actionable insights at the point of care. Therefore, treatment decisions become faster, more precise, and better informed by molecular evidence.
The USC Norris Comprehensive Cancer Center will be a primary site for this integration. Cancer care depends heavily on molecular profiling. Thus, oncologists stand to benefit most in the early phases of this collaboration.
What This Means for Patients
Patients at Keck Medicine of USC gain access to a higher standard of personalized care. AI-assisted trial matching means eligible patients no longer slip through the cracks. Furthermore, care gap detection ensures that preventive steps happen proactively rather than reactively.
Broader access to genomic insights also reduces health disparities. Historically, precision medicine tools reached wealthy or well-insured patients first. By embedding these tools into a high-volume public health system, USC and Tempus extend their benefits more equitably.
For cancer patients specifically, faster trial matching can be life-changing. Time matters enormously in oncology. Even a few weeks gained in finding the right trial can significantly influence outcomes.
Looking Ahead: Research and Innovation
This collaboration is not just about current clinical tools. It is also about building the foundation for next-generation diagnostics and treatments. Joint R&D will generate new datasets, validate AI models, and produce publishable research.
Both partners aim to publish findings and share learnings with the broader medical community. In turn, this open approach accelerates progress across the field. Additionally, it strengthens USC’s position as a leading academic medical center in AI-driven healthcare innovation.
Tempus, meanwhile, gains access to USC’s diverse patient population and clinical expertise. That access enhances the quality and breadth of its AI training data. Ultimately, both organizations emerge stronger from this alliance.
The Keck Medicine–Tempus AI partnership signals a broader trend. Health systems are no longer treating AI as a future investment. Instead, they are operationalizing it today — in workflows, trials, and diagnostics — to deliver measurable patient benefit right now.
